-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 27, 2021, AstraZeneca announced a collaboration with Regeneron to jointly develop and commercialize a new small molecule drug targeting GPR75 to treat obesity and related comorbidities
.
In a research paper published a few days ago in the top academic journal "Science", researchers sequenced the gene exomes of nearly 650,000 people and finally identified 16 rare gene mutations that affect the body mass index (BMI)
.
Among them, people who carry at least one inactive copy of GPR75 usually weigh 5.
3 kg lighter on average compared to individuals who do not carry the mutation, and face a 54% lower risk of obesity
The researchers further tested the effect of the GPR75 gene on body weight in mice
.
They knocked out this gene in mice, mimicking the lack of protein function
.
▲Mutant mice with one allele knocked out and both alleles knocked out have 25% and 44% lower weight gains than normal mice (picture source: reference [4])
The level of blood sugar control in mice that knocked out the GPR75 gene was also significantly enhanced
.
Therefore, inhibiting GPR75 may provide a new strategy for the treatment of obesity
.
Note: The original text has been deleted
Reference materials:
[1] AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity.
[2] Regeneron's latest genetics discovery hooks AstraZeneca — now all-in on developing small molecules for obesity.
[3] AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics.
[4] Parsa Akbari et al.
